Skip to main content
logo
Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
84.96
-0.22 (-0.26%)
Mar 23, 2026, 4:00 PM EDT - Market closed

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
United States Revenue
923.28M697.16M
United States Revenue Growth
32.43%32.41%
International Revenue
58.74M41.85M
International Revenue Growth
40.35%11.84%
Revenue (Total)
982.02M739.02M
Revenue (Total) Growth
32.88%31.04%

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Oncology Revenue
683.60M542.83M
Oncology Revenue Growth
25.93%34.40%
Biopharma and Data Revenue
210.13M177.58M
Biopharma and Data Revenue Growth
18.33%30.24%
Screening Revenue
79.73M5.12M
Screening Revenue Growth
1456.05%-
Licensing and Other Revenue
8.56M13.49M
Licensing and Other Revenue Growth
-36.51%-43.15%
Revenue (Total)
982.02M739.02M
Revenue (Total) Growth
32.88%31.04%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Precision Oncology Testing Revenue
-687.94M
Precision Oncology Testing Revenue Growth
-33.77%
Development Services and Other Revenue
-51.08M
Development Services and Other Revenue Growth
-2.78%
Revenue (Total)
982.02M739.02M
Revenue (Total) Growth
32.88%31.04%

Gross Profit

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Precision Oncology Testing Gross Profit
-427.36M
Precision Oncology Testing Gross Profit Growth
-38.43%
Development Services and Other Gross Profit
-21.86M
Development Services and Other Gross Profit Growth
--22.41%
Gross Profit (Total)
633.01M449.22M
Gross Profit (Total) Growth
40.91%33.34%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Clinical Test Sales Volume
276.00K206.70K
Clinical Test Sales Volume Growth
33.53%19.55%
Biopharmaceutical Test Sales Volume
-40.50K
Biopharmaceutical Test Sales Volume Growth
-35.45%
Updated Feb 19, 2026. Data Source: Fiscal.ai.